mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.072 |
0.05 |
mRNA |
manumycin A |
CTRPv2 |
pan-cancer |
AAC |
0.061 |
0.05 |
mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.067 |
0.05 |
mRNA |
ML210 |
CTRPv2 |
pan-cancer |
AAC |
-0.063 |
0.05 |
mRNA |
BRD-K48334597 |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.06 |
mRNA |
dinaciclib |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.06 |
mRNA |
BRD4132 |
CTRPv2 |
pan-cancer |
AAC |
-0.071 |
0.06 |
mRNA |
ML258 |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.06 |
mRNA |
Rapamycin |
gCSI |
pan-cancer |
AAC |
-0.099 |
0.06 |
mRNA |
ML203 |
CTRPv2 |
pan-cancer |
AAC |
-0.07 |
0.06 |